REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Data from REACH3 shows ruxolitinib significantly improves responses and symptoms at Week 24 in patients with cGVHD, and inadequate steroid response, when compared with BAT.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: December 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Commentary from Dr. John Leonard on factors he uses to select mantle cell lymphoma therapy, from Clinical Care Options (CCO)

John P. Leonard, MD Released: July 29, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Clinical commentary featuring expert insights on key CLL studies with BTK inhibitors from ASCO and EHA 2021 from Clinical Care Options (CCO)

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue